Full Transcript Introduction and Guest Background 0:07 Welcome back to the reversed Alzheimer's Summit. 0:09 I'm your host, doctor Heather 0:11 Sanderson, and I'm delighted to introduce you to Doctor Richard Pitre. 0:14 He's the CEO of Site Talks at Sites. 0:18 Richard has spent 25 years in the Alzheimer's disease 0:22 field, and is focused on developing novel genetic tests for assessing the 0:26 Alzheimer's disease risk. 0:27 The Gino Square test, developed in partnership 0:31 with Thermo Fisher Scientific and Sampled, is aimed at clinicians 0:35 assessing patients at risk of cognitive decline due to Alzheimer's disease. 0:39 In addition to pharma companies 0:41 seeking high risk patients for recruitment into clinical trials. 0:45 Over the past 25 years, Richard has developed diagnostic 0:48 and therapeutic products for GE, UCB, Caltech, 0:53 Laurentiis and Amersham. 0:56 Richard's academic training is from Bristol University 0:58 in the UK and Harvard Medical School. 1:00 Richard, thanks so much for taking the time to join us. 1:04 Pleasure. Thank you. 1:06 So I learned 1:07 about your test recently when I was at a conference, 1:10 and I was so excited that we could put a number 1:15 to this idea of risk. 1:18 Like how likely I can't tell you how many children 1:21 bring in their parent who's already suffering. 1:25 And they're sitting there wondering, well, what about me? 1:28 We have the same genetics, 1:29 or at least I've got half of her genetics in genetics or his genetics. 1:33 How worried do I need to be about this? 1:36 And should I get started on the program? 1:38 And so having a number to associate with that question 1:42 as an answer is so valuable for people. 1:46 Can you tell us a little bit about how you arrived 1:49 at creating this risk number?
How the Genetic Risk Score Was Developed 1:52 Sure. 1:53 I mean, the motivation here had, I mean, is very much around exactly 1:58 finding these patients at the earliest possible juncture when the chances 2:02 to intervene are likely to be, you know, far more efficacious. 2:06 And so those patients really, as you describe their fall 2:09 into two groups, you have the the symptomatic individual 2:12 who made themselves realize they have a problem. 2:14 Or it may be that they've been referred to, you know, by a loved one 2:18 or family member 2:19 or indeed a younger individual who has been aware of a parent 2:24 or grandparent that's been diagnosed previously and wants to know, as you said, 2:28 whether they've inherited this risk. 2:29 So what we do is we look and what we've developed 2:33 here is the most comprehensive description of genetic risk for late 2:37 onset Alzheimer's disease, or the common form of Alzheimer's disease, 2:42 typically manifests in, you know, people of 65 years and above. 2:45 But, you know, can actually a period little bit earlier sometimes. 2:48 The way this works is that there's been a genetic 2:52 mapping exercise that's gone on for, you know, the last ten years, really. 2:57 And through, a big consortium called the International Genomics 3:01 of Alzheimer Program. 3:03 And what we've been doing is collecting data from very large numbers 3:06 of age, match people, some of whom have Alzheimer's and some of whom don't. 3:11 And then doing effectively a piece of detective work to pick out 3:14 those genetic elements that seem to link to increased Alzheimer's risk. 3:19 Now, working through that data with academic collaborator and partners 3:23 in the UK, we've identified about 112,000 different DNA variants, 3:30 all of which we carry to some extent, which confer 3:33 a little bit of added risk or a little bit of reduced risk. 3:37 And what we've what we've basically built is an algorithm 3:41 that detects those variants, then adds them up in a weighted formula 3:46 to come up with a single number which describes genetic risk. 3:50 We then combine age and gender 3:54 to come up with what we call apologetic risk score or genus score. 3:57 That you mentioned. 3:59 So one being the highest risk, zero being the lowest risk, 4:03 and we can then essentially put people in different risk categories like that. 4:07 So most of our listeners are familiar with the about the genetic thing. 4:11 And this is I know something that you're testing. 4:14 How is your test different from just knowing your ApoE status. 4:19 Okay. So AP is a very important gene. 4:21 We all carry the AP gene and it comes in various different forms. 4:25 And and some of your listeners may know that if you inherit and you can, 4:30 you can buy a test today from 23 in May and, and find out whether you carry 4:35 one or more or two copies of the E4 version of the per week. 4:40 And if you do, there's no doubt you're a increased risk of Alzheimer's disease. 4:44 It's a key genetic contributor, but the problem is that you can carry E4 4:50 and still never develop Alzheimer's disease. 4:53 Conversely, about 40% of people that develop outside this disease 4:57 do not have E4 alone, so it's not a good descriptor of Alzheimer's genetic risk. 5:03 What we do is incorporate. 5:05 E4 is one of the 112,000 different elements 5:09 that we combine together to give a formal, accurate and descriptive genetic 5:14 risk profile for the risk of developing late onset Alzheimer's disease. 5:18 And we can look at that. 5:19 We published data in peer reviewed scientific journals, which shows 5:24 how much better we are picking out high risk individuals 5:28 with E4 or indeed high risk individuals without E4. 5:31 So we can differentiate to a far greater extent. 5:35 So I want to just break down some of these numbers 5:37 so that people can have a tangible kind of sense of what's going on here. 5:41 So if you have ApoE e4 for you have and please correct me 5:45 because you are the expert in this and I'm just a clinician over here. 5:49 So if you have E4 four four from mom, four from dad, 5:53 then you have about a one inch two chance, a 50% chance of developing 5:58 dementia over the course of your life if you have three four. 6:02 So just one copy. 6:04 So one from mom or dad, and then you don't have a four from mom or Dad. 6:08 You have a three or a two. 6:09 I don't think I've ever seen A24, but a 3 or 4 is pretty common. 6:13 Then you have a 1 in 3 chance of developing dementia. 6:18 The population at large has about a 13% chance 6:22 of developing dementia, so these are significantly elevated risks. 6:27 If you do not have a four, then my understanding is
ApoE vs Polygenic Alzheimeru2019s Risk 6:32 you have about a 9% risk. 6:33 So a little less than the general population. 6:37 So about a one inch ten risk. 6:40 Now what you're describing is, 6:45 creating a number that is even more specific to that. 6:49 So how do we know if you have A44? 6:51 Are you in the camp? 6:52 The with 50% that gets dementia or the camp. 6:56 That's the 50% that does. 6:57 And we know of course, we've been talking a lot on this summit 7:00 about all of the lifestyle factors that influence this. 7:03 However, these genetic factors and understanding them. 7:07 If we know that we actually have an 80% risk 7:10 or a 90% risk genetic of developing dementia, then we know 7:14 we want to work that much harder, that much earlier in our life. 7:17 To prevent this is that we know this, right? 7:21 Absolutely. 7:22 I mean, you know, if whatever test you're using, if it puts you into high 7:27 risk category, you need to remember that it's it's not a diagnostic test. 7:32 Okay? 7:32 So it is not predetermined that someone with a high polygenic risk 7:37 or even a low polygenic risk will or will not develop Alzheimer's disease. 7:40 You correctly mentioned that it's a combination, really, 7:44 of genetic input, but also lots of environmental 7:47 and comorbidities that contribute to overall Alzheimer risk. 7:51 The point is, if you test early and you find your a high genetic risk, 7:55 then the the rewards for taking on management, 7:59 proactive management of those other lifestyle environmental risks 8:03 are that much greater in terms of mitigating your overall risk, 8:06 either the time in which you might develop, 8:09 Alzheimer's disease or indeed the rate at which you're 8:12 decline associated with Alzheimer's disease might occur. 8:15 So let's go back to the employee story. 8:17 So you know, about 75, if you think about the Caucasian populace, 8:21 this is genetics get quite complicated quite quickly because 8:24 depending on ethnic background, you know, the influence can be a bit different. 8:28 But typically in a Caucasian population, 8:31 25% of the population carry one or more copies of the paper. 8:36 We four form of paper. 8:39 We, 75% of people carry none. 8:42 So let's take that 75% group. 8:44 If you're in that 75% group, you think you might be feeling quite smug. 8:47 You know, I'm very low risk genetically, 8:49 but we know about 40% of Alzheimer's disease comes from that group. 8:53 So in the absence of an E4 risk, how do you assess genetic risk? 8:58 Well, our test is able to identify people that don't carry E4 9:04 but have very much in the E4 like risk. 9:07 We can stratify in a sort of distribution. 9:10 Those at the high end of that curve, so we can pick out with clinicians, 9:15 those at highest risk who will benefit more from those sort of lifestyle. 9:18 You know, interventions and treatments of co-morbidities. 9:22 And conversely, we can pick out people that do carry E4 9:26 who were still at relatively lower genetic risk overall because they E4 risk 9:32 is mitigated by some of the other genetic elements 9:35 that they may have inherited from one parent or the other. 9:38 So so what we're describing here is a far more comprehensive 9:42 look at the genetic landscape in any individual, 9:46 and how that will contribute to a lifetime genetic risk. 9:50 Got it. 9:50 So if someone already is symptomatic, I see a lot of patients in their 70s 9:54 and 80s who are suffering in their children. 9:57 Adult children usually bring them in or a dear friend or caregiver. 10:02 And is there a reason for them to get this test? 10:06 If they already have symptoms, might they want to inform anyone genetically 10:11 related to them, or what's the utility for someone in that category? 10:16 So. So you may be aware of this publication that came out, in 2020, 10:21 there was a a Lancet commission 10:24 that was basically put together a meta analysis of all the data, 10:29 associated with the impact of these 10:32 lifestyle and co-morbidity treatments. 10:35 And they concluded that something like up 10:38 to 50% of the risk for Alzheimer's disease was modifiable. 10:43 Now, that's a huge amount. 10:44 You know, even in a high genetic risk individual,
Why Risk Matters for Prevention and Early Action 10:47 that's definitely a prize worth, you know, going for. 10:49 Right. 10:50 But the most important thing I think they published, in addition to 10:54 that, was that even in people with early symptoms, taking those 11:00 lifestyle, you know, modification steps, 11:02 even at that point in the symptomatic phase of the disease, still had, you know, 11:07 very managed, manageable and measurable benefit to the patient. 11:11 So a suggestion that you can actually reverse some of these 11:15 early symptoms, which is really exciting, and perhaps that's, 11:18 you know, your experience in your own clinic, which I know, 11:21 you know, you've spoken very eloquently about the past. 11:24 So I think that that's a really important thing to bear in mind 11:26 for a lot of this work from The Lancet Commission, which was taking the top 11:31 clinical, experts and scientists from across the world, US, Europe 11:35 and other places as well, and was a consensus document 11:39 with a huge number of authors, 11:41 I think, really went under the radar a little bit because of the Covid pandemic 11:44 and the unfortunate timing when it came out. 11:46 So a lot of clinicians, even specialist clinicians, have missed this. 11:50 And we need to go back and educate them and patients 11:54 about the benefits of this work, much of which stems back 11:58 from the so-called finger studies that, Professor Mia could tell. 12:02 So, Finland, now based in Sweden, actually, you know, 12:06 set up and managed over a number of years long term activation studies, 12:10 which identified some of these factors that can be modified, to change risk. 12:14 So that's, that's really, really important. 12:16 That's something that's available to everyone today. 12:20 Also, of 12:21 course, on the radar now is the possibility of, 12:25 you know, disease modifying therapeutics becoming available. 12:30 We know about the Biogen story, the FDA approval, 12:32 but as yet the lack of reimbursement for the fighting drug. 12:35 But there are other Biogen like drugs coming through. 12:39 Just last week, Eisai, actually submitted their, 12:43 their file, their dossier with the FDA for review. 12:46 We know that Eli Lilly. 12:48 We know that Roche and other companies 12:49 also have similar drugs coming through their pipeline. 12:52 So, you know, as well as these lifestyle modifications, genuine disease modifying 12:58 drug therapies, you know, maybe, you know, not too far away. 13:03 We all hope so. 13:04 And yet yet another reason to to want to understand risk, I think. 13:09 Yeah, there's there's refrain right from the conventional community, 13:14 at least as I see it, that there's nothing you can do. 13:17 And so why would you want to know your risk? 13:20 It will just stress you out. 13:21 Create a new problem. 13:23 If I'm a neurologist and I've got namenda and aricept 13:25 and those are my options, and really my message is to get your affairs in order 13:29 because this is just a down hill slope. 13:32 Then to understand risk really makes my job a lot harder, right. 13:37 So I'm not going to offer this test to people. 13:40 And yet what we're seeing in well-respected journals like The Lancet 13:44 is that there is so much that we can do. 13:48 And certainly I would I would sort of push back 13:51 that we don't have to wait for drugs like aducanumab to be available. 13:57 And that there really, I think will get even better outcomes 14:00 by addressing these modifiable risk factors, getting rid of whatever's 14:05 causing the inflammation, the plaques and tangle formation, and that ideally, 14:10 what we'll do in the future is as those drugs become available that reduce 14:14 plaques and tangles, the kind of scar tissue of inflammation in the brain 14:18 is it will do all of our work first to get rid of the inflammation. 14:23 And then we'll add those medications just temporarily to kind of clean up 14:28 that scar tissue and create space for neurogenesis and, and neuroplasticity 14:33 that can help patients, achieve, you know, dare 14:37 I say, a cure, or something, at least going in that direction. 14:43 So I'm wondering, do you see it kind of similar playing out similarly? 14:48 I absolutely do. 14:49 And I think, you know, we are not alone in believing this. 14:52 The the advent of the brain health clinic. 14:56 Which is really targeting people who, you know, today have no disease. 15:00 They have no symptoms. 15:02 But but they need to raise awareness about what 15:05 they what they may be in for in the future and then start managing that, 15:09 that outcome, the early present pre-symptomatic stages. 15:13 It's much easier to preserve or reduce the rate of decline of neuronal loss. 15:18 And it is to replace, and, and so anything we can do to help that, 15:23 I mean, you know, as well as the sort of various, 15:25 you know, dietary and lifestyle interventions, you know, just sort of 15:28 social and physical activity can have a huge impact. 15:31 You know, the lack of isolation, treatment for hearing loss has been shown 15:35 to have benefits as well. 15:36 Otherwise people tend to, you know, they're they're lacking a lot of, 15:39 you know, natural stimuli. 15:41 And it and it sort of forces them to, to interact less, which is not a good thing. 15:44 So all these things, you know, have very material benefit. 15:48 And, you know, that there are, 15:51 I think, a greater number of clinics and clinicians now recognizing this, 15:54 but there's still a lot of work to be done on educating people. 15:57 I was at World Dementia Council meeting in London about a month ago. 16:02 And when, you know, some of the authors of that Lancet Neurology report 16:06 stood up and talked about modifiable risk 16:09 in that sort of 40, 50, 60%, ballpark. 16:14 You know, even the experts in the room were quite surprised 16:17 and were wandering around in the coffee break talking about this number. 16:20 And and it's the price. It's there now. 16:23 It's it's as you said, 16:24 it's not dependent on FDA approval or reimbursement for kind of math. 16:28 It's it's something that we can all be doing today. 16:31 Right. 16:32 So how would does someone know if this is a test that they should do? 16:37 I mean, obviously from where I sit and like, everybody should do this, 16:40 everyone should know their Alzheimer's risk. 16:42 No matter what your age or genetic risk, so that you can be proactive. 16:46 But that may not be your answer.
Lifestyle, Modifiable Risk, and New Therapies 16:50 How do we know if this is a good test for someone? 16:53 Okay, well, so, 16:55 we don't make that decision ourselves. 16:57 What we do is if people come to us, I mean, we are telling clinicians 17:02 and experts about what the test can do, and then we leave it to that clinician 17:06 in discussion, 17:07 in consultation with their patient to decide whether it's right for them. 17:10 It's a big deal to know you're outside of a risk. 17:12 You cannot, know that risk, you know, and we don't want to 17:16 we don't want to leave people with that knowledge without professional 17:20 clinical support around them, which is why our business will only ever, 17:25 you know, sell this through, registered clinical practices. 17:28 You know, you might recall that when 23 me started 17:33 offering their apiary test some years ago, they got into trouble just for sort of 17:36 putting it out there, and then worried people were turning up 17:39 on their doctors doorsteps and creating a bit of a problem. 17:43 And of course, a lot of, you know, concern, you know, for, for, 17:46 for a lot of people as well. 17:48 So, so I think it's much better handled in that way. 17:51 And that's very much our, our plan. 17:54 That said, we are committed to, to telling people about the test and, 17:59 and if they have questions, then directing them to clinics 18:03 in their own locality who are registered and able to offer that test. 18:06 And in the US today we have about 70 clinics, registered to do that. 18:11 And that's that number is growing significantly every week. 18:15 So there is clearly a lot of appetite amongst the clinicians. 18:18 And I think ultimately amongst the general public to to understand that risk. 18:22 And so for someone listening, and we have some of the attendees 18:26 from Australia, all over Europe, the UK, the US, Canada. 18:32 So for someone listening around the world, 18:35 how would they go about finding a provider who offers this test? 18:39 Can they go to your website? 18:41 Yeah, there's information on 18:42 our website and there will be an inquiry button on the website. 18:46 So if they came to us, we could then direct them accordingly. 18:48 At the moment the registered we have, we have in North America, 18:52 it's mostly in the United States. 18:54 We have a couple of clinics in Canada, that have come online recently as well. 18:58 We've got, you know, fewer clinics in, Europe, in the UK at the moment. 19:04 But that's that's something that we are focusing on. 19:06 You mentioned Australia. 19:07 We don't have specific, 19:09 clinics registered there yet, 19:10 but there are clinicians that we're in discussion with, 19:13 you know, thinking about adding this to their to their services 19:16 that they can provide. So, yeah, there's there is global interest here. 19:19 One thing I should say, Heather, is that, at the moment, the validation work 19:22 we've completed and published has all been just through sample access and access 19:27 to appropriate data in the Caucasian ethnic background. 19:31 Now, this does not mean that the test will not work in other ethnic groups, 19:35 but we haven't yet proven that. 19:36 In fact, I met in London with my technical team just yesterday 19:40 to review where we are with generating data that will be able to 19:44 to publish and talk through, performance in non Caucasian ethnic backgrounds. 19:50 But that's coming very soon. 19:52 There's nothing to stop a clinician using this test 19:56 on someone from another, ethnic group. 19:59 But that actually at the moment we can't make, 20:01 you know, a lot of statements yet that are backed up by published data 20:06 on exactly how accurate test would be in that group and got it. 20:10 Got it. 20:10 That's really helpful to understand that. 20:13 And I appreciate you acknowledging that. 20:15 Right. 20:15 Because so much research is done on white men 20:18 and then extrapolated to say that this is the truth for everyone on the planet. 20:22 Well, and that's the problem. 20:24 But we do know, even if you just take the AP example, 20:26 that we covered earlier in this discussion, you know, we know 20:30 that EPO has a differential effect on different ethnic backgrounds, 20:33 probably because, you know, the rest of the genetics are having a, 20:38 a modifying effect from the AP for allele if people are carrying that. 20:43 So, so, so we need to and we in fact, we are at the moment just analyzing data 20:47 from those different groups so we can make adjustments 20:50 to the algorithm if needed, which, generates that score. 20:54 And it's not likely to be a kind of does work, doesn't work 20:58 situation is likely to be it works to, a greater or lesser extent. 21:02 And we need to be able to quantify that before 21:04 it can be used reliably in everybody. 21:07 And of course, we are absolutely committed to making this available on 21:09 the widest possible basis. 21:12 And then how much does this cost? 21:16 That's a great question that we get asked very regularly, 21:18 and it's one that we struggle to answer. 21:19 And I'll tell you why. 21:21 We provide this test to a clinic. 21:24 And that clinic then decides how much they want 21:27 to sell the test to the patient for. 21:29 So in some cases, that could be, you know, a simple 21:33 sort of past through time cost. 21:34 So, so, so, you know, but in other cases, the clinic 21:37 wants to add this into part of a much wider, set of services, you know, 21:43 diagnostic services and then possibly ultimately clinical management services. 21:48 So we know that some people offer, you know, lifestyle and sort of, you know, 21:53 dietary supplement type approaches as part of an overall treatment package. 21:58 And our test is therefore incorporated as one element of that. 22:02 So so 22:03 we don't really have a lot of visibility about what clinics are actually charging. 22:06 So we always direct the patient that comes to us to clinic. 22:11 And they can discuss, you know, what it is exactly 22:14 that clinic offers and whether that's appropriate for them. 22:18 And then what does it require in order to get the sample. 22:21 So is it as simple as saliva okay. Or what. 22:24 What do I have to do to get you the test so that you can run it? 22:29 This is a really simple thing actually. 22:31 And this is one of the beauties of the test. 22:32 It's, you know, it's readily available to everyone. 22:34 So, typically we send out a saliva collection kit to the clinic 22:39 or a bunch of kits so that the clinician is sitting on these, on these kits. 22:43 These are very simple. 22:45 You all to Covid testing. 22:46 Everyone is used to giving saliva samples. 22:47 Right. So these are really straightforward. 22:50 The clinic and the clinician may choose to administer the saliva collection. 22:54 Step in their own clinic with the patient in front of them. 22:57 Or in many cases, the clinic just simply forwards
Who Should Get Tested and How It Works 23:00 these test kits to the individual in their own home. 23:03 They're really simple to use, 23:05 and then you pop the sample into a UPS collection box. 23:08 It's pre labeled and goes to the reference lab, 23:12 which does the extraction of the DNA from the saliva sample. 23:16 So you know over 90% of the samples are collected that way. 23:20 If the clinic happens to have a blood sample already, 23:23 you know, in in store or something like that, 23:26 because they've seen the patient, you know, recently 23:28 and they have that blood for some other reason. 23:30 We can also use blood as the starting point. 23:33 What happens is the lab extracts DNA 23:35 either from the saliva or from the blood, and the results are exactly the same. 23:39 Regardless of that starting point. 23:40 But of course, most people would rather give a bit of saliva than have a needle 23:43 to extract some blood into that, or have, stuck up their nose into their brain. 23:49 We're all used to that, unfortunately. 23:51 And it's not the most pleasant thing. 23:53 I mean, and the other thing to bear in mind have been you 23:55 mentioned, you know, other tests as well that might be out there. 23:59 You know, most of them are far more invasive. 24:01 I mean, cerebrospinal fluid, you know, from a spinal tap 24:04 or even injection of a radioactive dye to look for these. 24:07 They'll build up with these amyloid and talc proteins in the brain 24:10 directly or indirectly. 24:12 These are very expensive and very invasive techniques, which, 24:16 you know, really not suitable for this sort of earlier stage, 24:20 you know, risk assessment, they may be used latterly, 24:24 you know, if people want to, to look more closely at, to dynamic changes. 24:28 So to see whether or not that risk has become manifest at the level of an ongoing 24:33 pathogenic pathogenic process or not, but these are not suitable for, 24:38 you know, the early phase of risk assessment, we would argue. 24:41 Well, in my understanding, is that genetics actually 24:43 are more predictive of symptomatic dementias, whereas the 24:47 the presence of beta amyloid plaques or tau proteins, whether you're 24:50 looking on imaging or looking in cerebrospinal fluid, 24:54 there are 30% of people over 65 have an plaques and tangles 25:00 present to have a diagnosis of dementia, regardless of their cognitive function. 25:04 So the utility of that, 25:06 from from where I sit and my understand ING of the literature at this point 25:10 is that your tests would actually be more helpful, not only less invasive, 25:14 but more helpful in predicting a cognitive decline. 25:19 Right. What we actually care about. 25:21 I think that's right. 25:22 I mean, I spent 15 years of my career with GE healthcare developing the amyloid 25:26 Pet imaging agents that allow you to to understand 25:29 whether someone's building up, you know, plaque in their brain or not. 25:32 And we've known for some years now that there's a 25:35 there's actually quite a good association between ApoE4 and amyloid deposition, 25:40 but not between a powerful amyloid and, you know, deposition 25:44 and cognitive decline, which is what, you know, most 25:47 people are really worried about when they come and see their physician. 25:49 So so we very much being careful to, to look at the ability to predict 25:54 cognitive decline associate 80 because that is the most, you know, see, 25:58 for most people the most serious, clinical consequence of the disease. 26:01 So, so for that reason, yes, we would agree with you that that, that, 26:06 not only is this important to the patient and their clinician, 26:10 but it's also important to pharma companies because if you're 26:12 recruiting into a clinical trial and that trial is powered 26:16 on whether a group of patients decline cognitively over the next 2 or 3 years, 26:21 you want to enrich that population for people most at risk of decline, 26:25 to show that your drug is actually having a beneficial effect there. 26:28 So for that reason, you know, we do to work with pharma 26:31 companies as well to help them understand, 26:34 you know, finding right patients for their trials 26:38 and also potentially to find, ultimately, genetic signals in a patient that links 26:42 to a specific response to that drug, which I think is the ultimate 26:47 kind of goal, really, in terms of personalized medicine, finding 26:50 precision, very precise medicine, very precision medicine. Yes. 26:54 This is so exciting. 26:57 To think about this idea, 27:00 I think we're socialized at this day, in this day and age, that 27:03 there's going to be a pill that's going to fix things. 27:05 And, I obviously, 27:08 don't feel like we're there yet. 27:11 Certainly. 27:12 But this collaboration between lifestyle medicine prevention 27:17 and then if you end up with cognitive decline to do all that work 27:22 and then add that extra layer of the pill or the I.V., 27:26 whatever it is that can be developed to make it a little easier. 27:31 Certainly is is a really, 27:33 really exciting thing to look forward to in the future. 27:37 And I appreciate that you were collaborating with pharma 27:40 to go in that direction. Right? 27:41 Because we need to get out of this dead end kind of trap around just reducing beta 27:46 amyloid and really shift the focus onto cognitive function. 27:50 How is this individual experiencing the world? 27:53 What are they able to do? 27:54 Is their executive function, 27:56 their is their memory, their do they recognize their children? 27:58 Those that's where the rubber meets the road, right? 28:00 This is what's really important to people. 28:03 I don't care if I die with a bunch of beta 28:05 amyloid plaque in my brain, if I my cognition is totally perfect. 28:09 And so to to see you collaborating with pharma, where as we're 28:14 kind of shifting out of this emphasis so much on plaques and tangles and towards 28:20 good cognition, it's just exciting. 28:24 I think it's, it's it's even more exciting than that in the sense that, you know, 28:28 we're beginning to recognize that Alzheimer's disease is a it's a phenotype. 28:32 It's we could describe it clinically, but it's probably different ways to arrive 28:36 at that phenotype. 28:37 Okay. 28:38 So and that means that, you know, perhaps not all individuals 28:41 with Alzheimer's disease are going to respond equally to one 28:44 particular drug intervention, particularly if we go early in the disease process. 28:48 You was testing it previously, you know, looking at inflammatory mechanisms. 28:52 You know, some inflammatory mechanisms may be driving the disease 28:56 in one individual or group of individuals, but not in others. 28:59 And so, you know, peeking out through genetics, 29:01 the right group for the right treatment, I think will be really important. 29:05 And, and of course, oncology and cancer drug development 29:09 has looked like this for 25 years, but we've been very slow in our own field 29:13 in Alzheimer's and dementia, 29:14 because we're only just really understanding and appreciating, 29:18 you know, the strong genetic drivers behind the disease. 29:20 It was not that long ago in conferences where, you know, you 29:24 you would struggle to find experts in the room who would accept that late onset 29:28 Alzheimer's disease had a strong genetic component,
Global Availability, Cost, and Sample Collection 29:30 whereas I think now that has completely changed. 29:32 So, you know, we are at a new dawn. 29:34 I think of drug development approaches for Alzheimer's treatment. 29:37 And, you know, we can only hope that there'll be a successful, 29:41 you know, new phase in that, in that effort. 29:44 And then you're, careful to say 29:47 late onset diagnosis of Alzheimer's. 29:50 So let's just speak a little bit to the early onset, 29:54 because I don't think you guys are checking for AP or the person's. 29:58 That's right. 29:59 So, so, you know, it basically is a rare form that runs in families, 30:04 early onset Alzheimer's disease, 30:06 which is specifically associated with mutations in one of three genes, 30:10 as you said, the amyloid precursor protein or ATP, for short 30:14 increase in the limb one increases in two genes as well, 30:17 which are involved in the metabolism and the chopping up opium, alloyed 30:21 into these sort of toxic fragments that ultimately form the plaques. 30:26 So, yeah, I mean, families that that 30:29 inherit those sorts of mutations tend to know that they, 30:32 you know, they tend to be causative rather than just risk associated, 30:37 although it's more complicated than that, because actually, 30:40 while there are causative mutations or other mutations which seem to be more, 30:44 you know, sort of less penetrative, in other words, you can have some 30:47 of these variants that don't necessarily cause early onset disease. 30:51 So at the moment, our test is not designed to pick those up. 30:54 So, it's not that we, you know, we're not interested from a research spectacle. 31:00 We have not validated 31:02 the ability of our particular platform, to identify those reliably. 31:06 And in fact, you know, the way that technology 31:09 works, it may not be the most appropriate for those things. 31:12 So I think, it's more likely that, 31:15 patients will be referred to other forms of, genetic testing 31:18 available in of teaching hospital type environments for that. 31:21 Fantastic, fantastic. 31:23 So what do you, I know we've talked a lot about looking forward and, 31:27 seeing kind of the future of the research in the future of drug development. 31:31 What are you most excited about? 31:33 You've spent decades in this field. 31:36 And like you said, it's a it's a new dawn. 31:38 So what do you hope it looks like when we're chatting ten years from now? 31:43 What I hope is that 31:44 centers like yours and, you know, and brain health 31:48 clinics in general are a phenomenon in everyone's life. 31:52 You know, it's just something we do. 31:54 It's been normalized. 31:55 Everybody knows at a certain point, you know, they're going to go 31:58 and check out their brain health, look for risk 32:00 and then take appropriate mitigating action. 32:03 You know, put the pharma companies out of business. 32:05 You know, we don't we don't want to be taking amyloid 32:06 busting drugs that you have to, you know, infuse because they're, 32:10 you know, antibody based drugs at the cost of, 32:12 you know, tens of thousands of dollars per patient per year. 32:15 It's not sustainable for health care systems to be able to provide that, 32:19 whether it's a national health system like we have in the UK, 32:21 or whether it's a more of an insurance backed CMS system in the US. 32:25 So I think prevention is going to be a huge part 32:28 of the solution to this kind of, you know, Sassoon army. 32:32 I mean, you know, if we think about the the financial and societal impact 32:36 of Covid up over the last couple of years, we're all fed to the fact that. 32:40 But that will pale into insignificance compared 32:42 with this of late onset Alzheimer's disease wave, which is going to hit us 32:46 because we're an aging population and the biggest, you know, lifestyle 32:51 risk for late onset Alzheimer's disease is old age, as you pointed out earlier. 32:55 So if we can understand at a younger age and when it's time to actually take steps 33:01 to reduce overall risk, that is going to have a huge impact 33:06 and be hugely beneficial to both the individual and society as a whole. 33:12 And the associated costs of looking after this. People. 33:14 Yeah. 33:15 So because we have this aging population, that's the fear of God. 33:19 And everyone of but there's not enough young people to take care of them. 33:22 All right. 33:24 So prevention and I just want to echo what you've said over and over 33:29 that my clinical experience is that the earlier we intervene, 33:32 the earlier in the disease process 33:34 and the younger someone is when they start to notice decline and start 33:37 to take action, the more confidence they have that they can fully recover. 33:42 And this becomes a lifestyle, right? 33:44 You can't fully recover and then slide back into a standard American diet and 33:48 and not getting in the exercise or stressing yourself out all the time. 33:53 But if we can maintain a brain healthy lifestyle, 33:57 then we can at the very least delay the onset of dementia
Ethnic Validation, Early-Onset Disease, and the Future 34:02 and at best stay cognitively cognitively fit for the rest of our lives. 34:07 And then you don't need that support that caregiving support that 34:11 that may not exist just because of the demographic shifts that are happening. 34:15 These radical demographic shifts across certainly the Western world. 34:20 But, my understanding is that every continent on the planet 34:23 is aging, except for Africa. 34:26 So there there are massive shifts in my lifetime, 34:29 and I hope that for my generation, I'm in my 30s, late 30s, and, 34:34 I would think that Alzheimer's is optional for us, with very rare exception. 34:39 And so working together to do the testing, to do as much risk mitigation 34:44 and prevention as possible for my generation, we should 34:49 get to a place where, like Doctor Bateson says, this is a rare disease. 34:53 And that that is worth looking forward to. 34:57 And certainly, because of these demographic shifts 35:00 that you and I both are privy to, I think a lot of people don't realize it. 35:04 Right, because it's not happening quite yet. 35:06 But you can see it on the horizon. 35:08 Certainly Germany and Japan are experiencing this, 35:13 that yeah, we have to do 35:15 something if we have to do something that needs to be a solution and fast. 35:19 Yes. And I think that's exactly what clinics like yours have come in, 35:22 you know, you know, we shouldn't pretend that some of these, you know, lifestyle 35:27 changes unnecessarily easy for everyone to actually having clinical oversight. 35:32 Well, first of all, I think having a 35:34 a test result that says, look, you know, you need to take this seriously. 35:37 You're in a high risk group, you know, don't panic that, you know, it's good. 35:40 We found this out at a relatively young age and you know, 35:43 but but now that you know this, take it seriously, okay. 35:47 And and but but even then, you know, having some oversight, 35:51 some clinical oversight, some regular interaction 35:54 with clinical professionals, I think is going to help. 35:57 We've seen this from, the American College of Genetics in other 36:02 disease areas that having that result, that's, understandable by the patient. 36:07 On the one hand, but actionable, on the other is critical 36:11 to, to, to sustaining that sort of healthy lifestyle. 36:15 So, you know, even in that early, you know, that patient 36:20 that you've described with early symptoms, it's not too late to do something. 36:23 But the prize perhaps, is, is that that, you know, that stage earlier 36:27 we know that amyloid and tau building up 20 36:30 or 25 years before symptoms occur, you know, and genetics 36:35 give you an even earlier insight into those most at risk, 36:38 most likely to end up with amyloid and time in their brains. 36:42 So, yeah, it's it's a huge opportunity that, is in front of this at the moment. 36:48 And our job, my job is to try and get the message out 36:52 about this test, about the value of it. 36:54 And, and talking to clinicians like you is absolutely a part of that. 37:00 Thank you so much for your time, Richard. 37:02 This has been very educational for me. 37:05 I've learned a ton. 37:06 It's a pleasure to speak with you and thank you 37:09 for sharing my passion and enthusiasm about this work. 37:13 There's a lot of work to be done, and it's nice to know that 37:16 there are smart, dedicated people like you around the world 37:20 who are working to create a solution to this problem. 37:23 So I want to make sure everyone knows the website to go to 37:28 if they want to make that inquiry about getting this test. 37:32 If you go to the, site talks website 37:36 dot six group.com, we will direct you accordingly, 37:40 to to the appropriate information that you may require, 37:44 talk to you about how the test works and, and then if you're still interested, 37:49 direct you to, to a clinic that's registered in your own locality 37:54 and it's called the Alzheimer's risk test, right? 37:57 That's right. Great. So, 38:01 again, thank you so much for 38:02 your time and for the work that you're doing in this field. 38:06 I couldn't be more grateful. It's been a pleasure. 38:09 My pleasure. Thank you very much. And.
Comments